TriSalus Life Sciences (TLSI) has issued an update.
TriSalus Life Sciences, Inc. and its subsidiary secured a $50 million loan facility through a credit agreement with OrbiMed Royalty & Credit Opportunities IV, LP. The agreement stipulates a staggered fund availability, with $25 million initially accessible and additional funds contingent on revenue targets. The loan, maturing in 2029, is secured by the company’s assets and includes provisions for interest rates, prepayment premiums, and default consequences. Additionally, the company granted stock purchase warrants to the lender, with rights and regulations detailed in the agreement, alongside a Registration Rights Agreement to enable stock resale.
For an in-depth examination of TLSI stock, go to TipRanks’ Stock Analysis page.
